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Chronic Trypanosoma cruzi infections are typically lifelong, with small
numbers of parasites surviving in restricted tissue sites, which include the
gastrointestinal tract. There is considerable debate about the replicative
status of these persistent parasites and whether there is a role for dormancy
in long-term infection. Here, we investigated T. cruzi proliferation in the
colon of chronically infected mice using 5-ethynyl-20deoxyuridine incor-
poration into DNA to provide ‘snapshots’ of parasite replication status.
Highly sensitive imaging of the extremely rare infection foci, at single-cell
resolution, revealed that parasites are three times more likely to be in
S-phase during the acute stage than during the chronic stage. By implication,
chronic infections of the colon are associated with a reduced rate of parasite
replication. Despite this, very few host cells survived infection for more
than 14 days, suggesting that T. cruzi persistence continues to involve
regular cycles of replication, host cell lysis and re-infection. We could find
no evidence for wide-spread dormancy in parasites that persist in this
tissue reservoir.1. Introduction
Disease latency, mediated by awide range of mechanisms, is a common feature of
viral, bacterial and parasitic infections [1–3]. However, there can be long-term
consequences for the host, which include relapse and/or inflammatory pathology.
The terms ‘persistent’, ‘dormant’ and ‘metabolically quiescent’ are used, often
interchangeably, to describe pathogens in this state. The phenomenon has evolved
independently and frequently in different pathogen groups, presumably
because it acts to enhance survival and transmission. The ‘persister’ phenotype
does not involve the acquisition of selected mutations, and is often associated
with treatment failure, antibiotic tolerance being the best studied example [4,5].
In the case of Chagas disease, some form of dormancy or restricted replication
has been widely postulated as a mechanism that might explain long-term parasite
survival and the high rate of treatment failure [6].
Chagas disease is caused by the protozoan parasite Trypanosoma cruzi, which
infects 6–7 million people, mainly in Latin America. Better drugs and innovative
immunological interventions are urgently required. Human infection is normally
initiated when faeces of the triatomine insect vector, contaminated with metacyc-
lic trypomastigote forms of the parasite, come into contact with the bite wound,
or when they are rubbed into mucous membranes. An acute parasitaemia
develops, which can be asymptomatic, or manifest as generalized symptoms
such as fever, headache and muscle pain. Suppression of the infection is then




2to extremely low levels [7,8]. A subset of infected individuals
(approx. 30%) eventually develop the classical Chagasic
cardiac and/or digestive symptoms, although this can be dec-
ades after the acute stage infection. Dilated cardiac myopathy
and digestive megasyndromes are the most common morbid-
ities, and can often be fatal [9,10]. It remains to be established
how the parasite is able to persist long term, albeit at very
low levels, in the face of a robust adaptive immune response
[11]. Furthermore, the reasons why treatment failures are
a common outcome needs to be better understood at a
mechanistic level to guide the design of improved chemother-
apy [12]. In this context, the recent report of a non-proliferative
form of T. cruzi that is refractory to treatmentwith the front-line
drug benznidazole [13] could have important implications.
The ability of human parasites to enter a long-term quies-
cent state, in which both replication and metabolism are
slowed, has been described in Toxoplasma gondii (the brady-
zoite) [14] and some Plasmodium species [3]. As with many
prokaryotic pathogens [15,16], the ‘dormant’ state involves
lower levels of DNA synthesis and transcription, downregula-
tion of energy catabolism and activation of DNA damage/
cellular stress responses. In T. gondii, a master transcription
factor (BFD1), activated by stress response pathways, initiates
the onset of bradyzoite development [17]. The precise triggers
that lead to differentiation into the quiescent hypnozoite liver
stage in some Plasmodium spp. have been elusive [3]. Among
eukaryotic pathogens, these examples represent one end of
the ‘dormancy spectrum’, in which entry into a quiescent
metabolic state is for extended periods. It has also been
tentatively proposed that Leishmania donovani can enter a
form of dormancy, although the mechanisms involved are
unknown [18]. The situation in other Leishmania spp. is more
definitive, with the identification of quiescent intracellular
amastigotes which exhibit a slower metabolic flux and
a reduced replication rate [19,20]. This stops short of full
long-term dormancy in which parasites enter G0/G1 cell
cycle arrest. Plasmodium falciparum blood stage schizonts can
also enter a transient state of dormancy, induced by treatment
with the front-line drug artemisinin [21,22]. This capacity to
respond to stress by halting progress through the cell
cycle exists in most cells that have DNA damage sensing
machinery [23,24]. The existence of a dormant phenotype
in the African trypanosome, Trypanosoma brucei, beyond
the G0/G1 arrested stumpy form required for onward
transmission [25] remains speculative.
Observations of both in vitro and in vivo T. cruzi infections
identified a subpopulation of non-dividing intracellular
amastigotes that retained the ability to differentiate into
flagellated trypomastigotes, which were then able to propa-
gate the infection [13]. This phenomenon was defined as
spontaneous dormancy on the basis of experiments that
involved monitoring incorporation of the thymidine analogue
5-ethynyl-20deoxyuridine (EdU) into replicating DNA,
and use of the tracker dye CellTrace Violet (CTV) to mark
non-dividing parasites. Whether this represents long-term
metabolic quiescence analogous to that in T. gondii and
Plasmodium spp., a slow-replicating phenotype as in Leishmania
spp., or temporary arrest induced by stress, as exhibited
by P. falciparum and all non-tumorous mammalian cells, is
unresolved. In this latter context, the report that T. cruzi
amastigotes have an intrinsic ability to reduce their replica-
tion rate by temporary cell cycle arrest in G1, as a response
to stress, nutrient availability and drug treatment, maybe of relevance [26]. It is not known whether these represent
overlapping or distinct mechanisms for entering a quiescent
state. This could have implications for drug design,
immunological interventions and our understanding of
T. cruzi persistence.
Using highly sensitive bioluminescence and fluorescence
imaging [27–29], we demonstrated that the gastrointestinal
tract, specifically the colon and stomach, is a key site of
T. cruzi persistence during chronic murine infections. Smooth
muscle myocytes in the circular muscle layer of the colonic
gut wall are the predominant host cell type. In the chronic
stage, the entire colon typically contains only a few hundred
parasites, often concentrated in a small number of cells that
can contain greater than 100 parasites. During the acute
stage, however, when the parasite burden is considerably
higher andmany cells are infected, host cells containing greater
than 50 parasites are rarely found. Persistent parasites are
also frequently detected in the skin during chronic infections,
and in C3H/HeN mice, the skeletal muscle [29,30]. Further
studies have also shown that parasite replication is asynchro-
nous in individual host cells, a process that is independent
of tissue location or disease stage, that replication of the
nuclear and mitochondrial genomes is non-coordinated
within the intracellular population and that replicating amasti-
gotes and non-replicating trypomastigotes can coexist in the
same cell [31].
We have developed tissue processing protocols and
imaging procedures that allow us to routinely detect
T. cruzi persistence foci during chronic murine infections at
single-cell resolution [28,29]. Here, we describe experiments
which provide new insights into parasite persistence, and
indicate that chronic infections are associated with a reduced
rate of parasite replication.2. Methods
2.1. Parasites, mice and cell lines
The T. cruzi bioluminescent:fluorescent lines CL-Luc::mNeon
or CL-Luc::Scarlet [28] were used throughout. Epimasti-
gotes were grown in RPMI-1640, supplemented with 10%
fetal bovine serum (FBS, BioSera), haemin (17 µg ml−1), trypti-
case (4.2 mg ml−1), penicillin (100 U ml−1) and streptomycin
(100 µg ml−1), at 28°C.Metacyclic trypomastigotes were gener-
ated by culturing epimastigotes to stationary phase. In vitro
studies were performed with the MA104 and Vero African
green monkey kidney cell lines. In vivo experiments were car-
ried out using female C3H/HeN mice, initially aged 8–12
weeks, purchased from Charles River (UK). Mice were main-
tained under specific pathogen-free conditions in individually
ventilated cages, with a 12 h light/dark cycle. They had
access to food and water ad libitum.
2.2. CellTrace Violet in vitro assay
Trypanosoma cruzi trypomastigotes were isolated by centrifu-
gation and allowed to recover for 2 h at 37°C in high-glucose
DMEM medium with 10% FBS, and then labelled with
CTV fluorescent dye (Thermo Fisher Scientific), according
to the manufacturer’s protocol. Briefly, 2 × 106 trypomasti-
gotes were washed in PBS and then incubated for 20 min




3Unbound dye was quenched by the addition of one
volume FBS and incubating for 5 min at 37°C. After washing
(×2) in fresh complete medium, trypomastigotes were
used for infection. Vero cells maintained in RPMI 10% FBS
were trypsinized and seeded at 104 or 105 cells per
well in 24-well plates containing coverslips, or in eight-well
Ibidi µ-slides, and allowed to attach for 6 h before infection.
Trypomastigotes were added at a multiplicity of infection
(MOI) of 10 : 1 (parasite : host cell) and allowed to invade
overnight (16–18 h). Cultures were then washed with PBS
(×3) to remove non-invading parasites, and infected cultures
incubated in RPMI with 2% FCS. Coverslips were fixed at
different timepoints by transfer into a plate containing 4%
paraformaldehyde for 30 min, then stained and mounted for
microscopy using Vectashield® with DAPI, or with propidium
iodide following RNase treatment.
Images and videos were acquired using an inverted
Nikon Eclipse microscope. The slide containing the infected
cells was moved along the x–y plane through a 580 nm
LED illumination. Images and videos were collected using
a 16-bit, 1-megapixel Pike AVT (F-100B) CCD camera set in
the detector plane. An Olympus LMPlanFLN 40x/1.20 objec-
tive was used to collect the exit wave leaving the specimen.
Time-lapse imaging was performed by placing the chamber
slide on the microscope surrounded by an environmental
chamber (OKOLab cage incubator) maintaining the cells
and the microscope at 37°C and 5% CO2. Video projections
and Z-stack sequences were created using the deconvolution
app in the Nikon imaging software.2.3. In vitro parasite culturing and EdU labelling
Tissue culture trypomastigotes (TCTs) were derived after
infecting MA104 cells with metacyclic trypomastigotes.
MA104 cells were cultured in Minimum Essential Medium
Eagle (MEM, Sigma-Aldrich), supplemented with 5% FBS
at 37°C, in 5% CO2. Twenty-four-well plates containing cov-
erslips were seeded with 105 cells per well and left for 48 h.
After reaching 95–100% confluency, they were infected with
TCTs at an MOI of 5 : 1 (parasite : host cell). Eighteen hours
later, external parasites were removed by washing (×3),
fresh supplemented MEM was added and the infections
allowed to proceed.
EdU (Sigma-Aldrich) in PBS was diluted to the appropri-
ate concentration in supplemented MEM. The medium was
removed, and the infected monolayer washed (×2), and
fresh medium including EdU was added. After the appropri-
ate incubation period, cells were washed (×3). For EdU
toxicity studies, parasite growth in infected cells was assessed
in 96-well plates, 3 days after EdU addition, by measuring
mNeonGreen fluorescence in a FLUOstar Omega plate
reader (BMG LABTECH). Background fluorescence was
calculated using uninfected MA104 cells (n = 6). For
microscopy, cells in the 24-well plates were washed (×2)
and incubated for 45 min in 4% paraformaldehyde diluted
in PBS. Coverslips were then removed and washed (×2) in
PBS. EdU incorporation was assessed using a Click-iT Plus
EdU AlexaFluor 555 Imaging kit (Invitrogen), as per the
manufacturer’s instructions, followed by washing (×2) with
PBS, with coverslips then mounted in Vectashield. To allow
precise counting of amastigotes, cells were imaged in three
dimensions with a Zeiss LSM880 confocal microscope,using the Image Browser overlay function to add scale bars.
Images were exported as TIF files to generate figures.2.4. In vivo infections
CB17 SCID mice were infected with 1 × 104 T. cruzi CL-Luc::
mNeon TCTs and monitored by bioluminescence imaging
[32]. At the peak of infection (approx. 18 days), when blood-
stream trypomastigotes were visible by microscopy, the
mouse was euthanized [33] and infected blood obtained by
exsanguination. Trypomastigotes were washed in Dulbecco’s
modified Eagle’s medium, diluted to 5 × 103ml−1, and CH3/
HeN mice injected i.p. with 1 × 103 trypomastigotes.2.5. In vivo EdU labelling
The standard 1-day EdU treatment involved two i.p. injec-
tions (12.5 mg kg−1 EdU in PBS) delivered 6 h apart. The
second injection took place 18 h prior to sacrifice. For the
3.5-day treatment, the daily injection protocol (above) was
extended for 3 days, with a final single injection on day 4, fol-
lowed 4 h later with euthanization and necropsy. For acute
stage experiments, mice were 14–16 days post-infection
when EdU was administered, and for the chronic stage,
mice had been infected for greater than 100 days. Organs
and tissues were subjected to ex vivo imaging, bioluminescent
foci from skeletal muscle and the colon were excised and pro-
cessed for histology [33]. Where indicated, whole colons were
removed from the gastrointestinal tract, split longitudinally,
pinned luminal side up and the mucosal layer removed.
Whole mounting of the entire external colonic gut wall
was performed as described previously [29]. Parasites were
identified by mNeonGreen fluorescence using confocal
microscopy, and carefully removed, together with approxi-
mately 5 mm2 of surrounding tissue. Prior to a second
mounting, tissue pieces were processed for EdU detection
in accordance with the manufacturer’s instructions [31]. Sev-
eral tissue segments could be developed for visualization
using 500 µl of Click-iT reaction mix.2.6. Statistics
All statistical analyses were performed in GraphPad PRISM
v. 8.0 and STATA v. 16.0., and the data expressed as the
mean ± standard deviation of mean (s.d.), unless otherwise
stated. In vitro EdU toxicity was calculated as % growth rela-
tive to non-treated controls. The data were fitted with a
sigmoidal function with variable slope and the absolute
IC50 value calculated by solving the function for X when
Y = 50%. All data were tested for normality and homogeneity
of variance using Shapiro–Wilk’s and Levene’s tests, respect-
ively. Statistical comparisons between samples to analyse
in situ EdU incorporation were performed using one-way
ANOVA with post hoc Tukey’s test for multiple comparisons.
Datasets were analysed by non-parametric tests when var-
iances were not homogeneous. The % EdU incorporation in
colon tissue sections versus whole mount were compared
using the Wilcoxon signed-rank test. The Kruskal–Wallis
test was performed on the data in figure 6. Statistical signifi-
cance was accepted where p≤ 0.05 (*p≤ 0.05, **p≤ 0.01,
***p≤ 0.001, ****p≤ 0.0001).
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Figure 1. CTV reduces T. cruzi infectivity and inhibits intracellular proliferation. (a) Trypanosoma cruzi CLBr-Luc::Scarlet trypomastigotes were incubated with either
5 or 10 µM CTV for 20 min and used to infect Vero cell monolayers at an MOI of 10 : 1 (Methods). Eighteen hours later, infection efficiency was determined by
inspecting a total of 2203 (control), 3781 (5 µM) and 3840 (10 µM) Vero cells (greater than 300 infected cells in each case). Each data point corresponds a randomly
acquired image and represents the mean percentage of cells infected. Differences between columns were analysed using a parametric one-way ANOVA with Tukey’s
post hoc pair-wise comparisons. ****p≤ 0.0001. (b) Vero cells infected with CTV−ve or CTV+ve trypomastigotes (as above) were incubated for the time periods
indicated. The numbers of amastigotes per infected cell were then determined by analysing greater than 300 infected cells per treatment. Error bars represent the
standard deviation from the mean. Data were analysed using a Wilcoxon rank-sum test. (c) Images of Vero cells 36 h after infection with CTV−ve (control) or
CTV+ve trypomastigotes. Red, fluorescent T. cruzi amastigotes. Fluorescent parasites containing the CTV tracer dye appear as purple on a red fluorescent background.
Size bars, 20 µm. (d ) Images of Vero cells 5 days after infection with trypomastigotes that had been incubated with various concentrations of CTV, as indicated.






3.1. The CellTrace Violet tracker dye inhibits T. cruzi
proliferation
We sought to explore parasite replication by using CTV, a
tracker dye that has been employed as a marker for spon-
taneous dormancy in T. cruzi amastigotes [13]. This
succinimidyl ester dye diffuses into cells, binds covalently to
the amine groups of proteins and becomes fluorescent follow-
ing cleavage by intracellular esterases [34]. CTV fluorescence
undergoes serial dilution with each round of parasite cell div-
ision, resulting in an inverse correlation between dye retention
and proliferation rate. However, reports that CTV itself can
inhibit cell division [35] prompted us to first investigate toxicity
towards T. cruzi. Trypomastigotes were labelled by incubation
for 20 min in 5 or 10 µM CTV (Methods), conditions that had
been used previously to monitor parasite proliferation [13].
When these parasites were added to the Vero cell monolayer,
we found they were 60% less infectious than trypomastigotes
that had been incubated in the DMSO solvent alone (figure 1a).
In the first 48 h post-infection, there was then limited division
of intracellular CTV+ve parasites, with most trypanosomes in
a state of growth arrest (figure 1b,c). By 72 h, replication had
been more widely initiated, although the average number of
amastigotes per infected cell was still significantly below that
of the controls (figure 1b). Microscopy also revealed extensive
heterogeneity in the intensity of CTV staining within theT. cruzi population, with many parasites failing to replicate,
particularly in the first 36–48 h post-infection. At lower CTV
concentrations (1 and 2 µM), growth inhibition was less
evident and fewer parasites retained the dye at 5 days post-
infection (figure 1d ). Collectively, these experiments indicate
that CTV is an inhibitor of trypomastigote infectivity and
amastigote replication, and that the use of dye retention as a
marker for dormancy and cell cycle arrest could lead to ambi-
guity. Furthermore, the heterogeneous nature of T. cruzi CTV
staining, even within individual host cells (figure 1c,d), could
result in differential growth and development rates within
the same intracellular parasite population. Prior to infection,
we removed non-bound CTV by quenching with addition
of bovine serum (Methods). Despite this, some dye was taken
up by mammalian cells and retained in stained vesicles for
several days (figure 1d; electronic supplementary material,
figure S1 and video S1). It was important to ensure co-
localization of blue (CTV), red (fluorescent parasites) and/or
green (DAPI-DNA) staining to avoid the risk of confusing amas-
tigotes and spherical CTV-containing vesicles, both of which
appear motile in the highly dynamic cytoplasmic environment.
3.2. Continuous EdU exposure can inhibit amastigote
replication in vitro
We then used the thymidine analogue EdU tomonitor parasite
proliferation. In T. cruzi, incorporation of EdU provides a read-
out on the replicative status of both nuclear and mitochondrial
6 h exposure + 3 days culturing 
IC50 = 1.67 µM
kDNA
n
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Figure 2. EdU incorporation by T. cruzi amastigotes in vitro is rapid, heterogeneous within the population and can inhibit parasite growth. (a) Trypanosoma cruzi
CL-Luc::Neon trypomastigotes were used to infect MA104 cells at an MOI of 5 : 1 (Methods). Two days later, cultures were exposed to EdU (50 µM) for 10 min, and
then examined by confocal microscopy. The image shows adjacent infected cells where in one instance, all eight amastigotes are EdU+ve, whereas in the other, 2/8
are EdU−ve (indicated by white arrowhead). N, host cell nucleus. (b) EdU labelling of amastigotes after 1 h exposure (40 µM). kDNA, kinetoplast DNA; n, parasite
nucleus. (c) EdU labelling of amastigotes after 6 h exposure (10 µM). Scale bars, 10 µm in all cases. (d ) MA104 cells were infected with trypomastigotes, and 2 days
later, the cultures were exposed for 6 h to EdU at a range of concentrations, and then washed thoroughly. After a further 3 days incubation, amastigote growth was
determined by assessing expression of the mNeonGreen reporter (Methods). The inhibition curve was plotted using GraphPad Prism to establish the concentration of





DNA (kDNA) [28,31]. However, the procedure has to be used
with caution, since EdU exposure in vitro can be associated
with toxicity. In culturedmammalian cells, this is characterized
by genome instability, DNA damage and cell cycle arrest
[36–38]. Short-term exposure at lower concentrations (less
than 12 h, less than 10 µM) appears to have less impact, and
does not perturb cell cycle kinetics [39]. Toxicity against
T. cruzi in vitro has also been shown to be dependent on
exposure time; 4 h had only minor inhibitory effects on intra-
cellular amastigotes, even at 70 µM, whereas with 24 h
continuous exposure, the IC50 dropped to 70 nM [40]. By con-
trast, when infected cells were cultured for 72 h in the presence
of 100 µM EdU, there was no reported inhibition of amastigote
replication [13]. Given these conflicting observations, as a pre-
liminary to in vivo studies, we assessed the in vitro kinetics and
growth inhibitory effects of EdU on intracellular amastigotes of
T. cruzi CL-Luc::Neon (a derivative of the CL Brener strain).
This parasite reporter line expresses a fusion protein that is
both bioluminescent and fluorescent [28]. After only 10 min
exposure, amastigotes were clearly labelled, and it was poss-
ible to distinguish those that were EdU+ve from those that
were EdU−ve (figure 2a). Similar heterogeneity, including
differential labelling of nuclear and kDNA, was observed
when infected cells were labelled for 1 or 6 h at different EdU
concentrations (figure 2b,c). This pattern results from asynchro-
nous amastigote replication [31], with EdU negativity/
positivity determined by the position of individual parasites
within the cell cycle during the period of exposure. When we
assessed the extent of EdU growth inhibition after 6 h
exposure, washing and examination 3 days later, we estab-
lished an IC50 of 1.67 µM, although the level of inhibition
plateaued at 70% (figure 2d). These outcomes are, therefore,
consistent with those reported by Sykes et al. [40].3.3. Reduced numbers of T. cruzi in S-phase during
chronic stage of infections
Wenext compared the dynamics of EdU incorporation bypara-
sites during acute and chronic murine infections with the
T. cruzi CL-Luc::Neon strain. The elimination half-life (T1/2)of EdU inmice has not been determined, but with other thymi-
dine analogues, the period is relatively short. For example, the
bioavailability of bromodeoxyuridine (BrdU), a thymidine
analogue also used in DNA labelling experiments, is less
than 15 min [41]. Infected C3H/HeN mice were, therefore,
given two EdU injections (each of 12.5 mg kg−1), 6 h apart
(figure 3a), in an attempt to highlight a greater number of para-
sites where DNA replication was underway. At any one time,
as judged by in vitro experiments, approximately 25–30% of
amastigotes will be in S-phase [26]. In the majority of cases,
the external gut wall mount methodology [29] was used to
process the resulting tissue samples. The protocol enables
the muscular coat, including the longitudinal and circular
smooth muscle layers, which contain the majority of colon-
localized parasites during chronic stage infections, to be visual-
ized in their entirety at a three-dimensional level with single-
cell resolution (Methods). Intracellular parasite numbers can
be determined with accuracy by confocal microscopy using
serial Z-stacking (electronic supplementary material, figure
S2). On occasions, infected host cells in colonic tissue were
also investigated by coupling ex vivo bioluminescence-guided
excision and confocal microscopy (Methods) [31].
Colon samples were excised 18 h after the second injection,
and the incorporated EdU visualized (Methods). We observed
significantly greater levels of parasite labelling in tissue
obtained from acute stage mice than from those that were
chronically infected (70% versus 20%) (figures 3 and 4; elec-
tronic supplementary material, figure S3). Therefore, during
the acute stage, a greater fraction of the parasite population is
replicating their nuclear and/or mitochondrial DNA at any
specific time point. By inference, the amastigote replication
rate must be slower during chronic infections, at least in this
tissue location. There were no differences in the data derived
from colonic tissue processed by the two differing method-
ologies (grey and yellow dots, figure 3b). We further observed
that during the acute stage, there was a positive correlation
between the number of parasites per infected cell and the
percentage of parasites where DNA synthesis was ongoing
(figure 4a–c). Large parasites nests were less common during
the acute stage, with few instances where infected cells con-
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Figure 3. Intracellular T. cruzi replication, as inferred by EdU incorporation, is slower in the chronic stage than during acute infections. (a) Schematic showing
experimental outline. C3H/HeN mice infected with T. cruzi CL-Luc::Neon were injected with EdU as indicated during the acute (15 days post-infection; dpi) or
chronic stage (greater than 100 dpi). Each larger red arrow indicates 2 i.p. injections separated by 6 h. (b) Percentage of parasites that were EdU+ve under
each treatment protocol. Colonic tissue was extracted from mice 18 h after the second injection (1-day treatment) or 4 h after the final injection (3.5 days treatment),
and infected cells detected by ex vivo imaging and confocal microscopy (Methods) (electronic supplementary material, figure S2 and table S1) [29]. Each data point
represents a single mouse. Blue data points indicate mice aged approximately 150 days at the start of acute infection, and act as age-matched controls. In the
chronically infected mice, yellow data points indicate colons processed by standard histological sectioning, and grey points highlight those processed through peeling
away of the mucosal layer and whole mounting the remaining colonic gut wall (Methods). No significant differences were observed in the % EdU+ve parasites in
colonic sections processed by each method (Wilcoxon rank-sum test). For comparison of treatment conditions, statistical analysis was performed as described
(Methods); ****p≤ 0.0001 and **p≤ 0.01. (c) Representative images of infected colonic muscle cells from an acute stage mouse. Labelling: parasites, green;
DNA, blue (DAPI staining); EdU, red. EdU labelling on a green background appears yellow. (d,e) Images of infected colonic muscle tissue from chronically infected









1–10 735 2260 18 87
11–25 108 1789 16 270
26–50 46 1655 10 355
51–100 9 526 5 344
101–200 0 0 2 324











































Figure 4. The inferred parasite replication rate is higher during the acute stage and correlates positively with nest size at this phase of the infection. (a) The number
of infected cells (nests) detected in colonic gut wall tissue from mice in the acute (n = 5) and chronic (n = 7) stage, and the number of parasites found in each
category (see also electronic supplementary material, table S1). Tissue was processed using the colon peeling procedure (Methods). (b) Percentage EdU+ve parasites
in infected cells during acute and chronic infections in relation to nest size. (c) Relating nest size to the % EdU+ve parasites during acute stage infection. Each point






quantify, for comparative purposes, the relative level of EdU lab-
elling in each parasite. However, since most images were taken
with whole mounted tissue sections, the variable depths of
parasites from the surface made this technically challenging.
As judged by visual inspection, the majority of EdU+ve
parasites in any one cell were labelled to a similar extent(figure 3c–e; electronic supplementary material, figure S3).
Since smooth muscle cells, the most frequently infected cell
type in the colon [29], are typically in a state of cell cycle
arrest, the nuclei of host cells were generally unlabelled.
In chronically infected mice, only a minority of parasites
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Figure 5. Increased chronic stage EdU incorporation by parasites with the 3.5-day protocol. (a) Level of EdU incorporation in the 55 infected cells detected in the
whole mounted colonic gut walls from seven chronic stage mice treated with the 1-day labelling protocol. The total parasite content (grey) and the number that
were EdU+ve (red) are indicated. (b) Upper images; an infected cell containing no EdU+ve parasites after labelling with the 1-day protocol. Lower images; an
infected cell from the same colonic tissue that contained EdU+ve parasites (see also electronic supplementary material, figure S3 and table S1). Parasites, green.
(c) EdU incorporation in 52 infected cells detected in six chronically infected mice treated with the 3.5-day labelling protocol. Every infected cell in the colonic gut





electronic supplementary material, figure S3), and in approxi-
mately 20% of infected cells, none of the parasites were
labelled (figure 5a,b). A similar level of heterogeneous incorpor-
ation was observed in skeletal muscle, another site of parasite
persistence in chronically infected C3H/HeN mice, and a
tissue where parasites are often found in large nests (electronic
supplementary material, figure S4, as example). When labelling
was extended over 3.5 days (a total of seven injections)
(figure 3a), therewas a 2.3-fold increase in thenumberof labelled
parasites, with approximately half of those in the colon being
EdU+ve (figures 3b and 5c; electronic supplementary material,
figure S3). With this more prolonged protocol, every infected
host cell that we examined contained at least one labelled para-
site (figure 5c). However, the percentage of EdU+ve parasites
within the population was still significantly lower than during
the acute stage, when the 1-day labelling protocol was used
(figure 3). In combination, these data indicate that during
chronic infection of the colon, there is a general reduction in
the number of parasites in S-phase. As judged by biolumines-
cence ex vivo imaging of organs and tissues, neither the 1-day
nor the 3.5-day EdU injection protocols had any detectable
effect on the levels of infection or on tissue-specific parasite
dissemination (electronic supplementary material, figure S5).
3.4. Long-term infection of individual colonic
smooth muscle cells is not common during
the chronic stage
To further investigate parasite replication during chronic stage
infections, we undertook experiments to assess the extent and
stability of parasite labelling 7 and 14 days after EdU injectionusing the 1-day labelling protocol (figure 6a). When mice were
examined by ex vivo bioluminescence imaging after 14 days,
there had been no measurable impact on the parasite burden
or tissue distribution (electronic supplementary material,
figure S5). At 7-day post-injection point, EdU+ve parasites
were still readily detectable, although there was a fourfold
decrease in their relative abundance within the population,
and only approximately 40% of infected cells contained any
labelled parasites (figure 6b,c,e,f ). By 14 days post-injection,
out of the 87 infected cells detected in the colons of eight
mice, just one contained EdU+ve amastigotes (figure 6d,e,g).
Using serial Z-stacking, we established that this infected cell
contained 82 parasites, 42 of which were labelled. Given this
profile, the most likely explanation is that this host cell had
remained infected for at least 14 days, with the parasites in a
state of low proliferation. The EdU+ve parasites cannot have
undergone many replication cycles during this period,
since the labelling intensity was similar to that in parasites
examined 1-day post-injection. Furthermore, in dividing cells,
incorporated nucleosides become undetectable after two to
five generations, assuming random segregation of daughter
chromosomes [42,43]. It can be further inferred from the
rarity of cells containing EdU+ve parasites (figure 6d,g), that
long-term occupancy of individual colonic smooth muscle
cells by T. cruzi is not a common feature of chronic stage infec-
tions, even though this tissue is a site of parasite persistence.
In the vast majority of cases, therefore, the normal infection
cycle of parasite replication, host cell lysis and re-infection
appears to continue during the chronic stage, albeit at a
reduced rate. Finally, the observation of multiple labelled
amastigotes within a single host cell 14 days after injection
(figure 6d) demonstrates that EdU is stable once it has been
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Figure 6. EdU labelling experiments reveal that parasite occupation of colonic host cells during chronic stage infections is not long term. (a) Schematic of the
labelling protocol. EdU was injected in two 12.5 mg kg−1 doses, 6 h apart (as in figure 3a). After 1, 7 or 14 days, mice were sacrificed, colonic tissue excised, and
infected cells detected by ex vivo imaging and confocal microscopy (Methods). (b) Representative images of parasite EdU incorporation following the 1-day labelling
protocol (see also figure 3d ). (c) EdU incorporation assessed 7 days post-injection. (d ) Left-hand image; EdU incorporation assessed 14 days post-injection. Typically,
infected cells contained no EdU+ve parasites. Right-hand image; the single example of an infected host containing EdU+ve parasites after an exhaustive search of
colon mounts from eight mice. Scale bars, 20 µm. (e) Mean % EdU+ve parasites found in infected colonic cells. Each data point represents a single mouse; 1-day
post-injection, n = 10; 7-day post-injection, n = 6; 14-day post-injection, n = 8. The total number of parasites detected, imaged and designated as EdU+ve or
EdU−ve in each mouse varied from 47 to 2468, with an average of 608. The yellow data points indicate colons processed by standard histological sectioning,
and grey data points highlight those processed through peeling away of the mucosal layer and whole mounting of the remaining colonic gut wall (Methods).
Statistical analysis of treatment conditions was performed as described (Methods); ****p≤ 0.0001. There was no significant difference (n.s.) between the
7- and 14-day post-injection groups. ( f ) Percentage parasites that were EdU+ve in infected colonic cells from mice sacrificed 7 days post-injection (n = 3).
Grey bar indicates the total parasite number in each infected cell; red bar indicates the percentage EdU+ve. (g) Similar analysis of EdU positivity in infected





incorporated into the T. cruzi genome, and that it is not readily
susceptible to removal by metabolic or DNA repair pathways.
This stability has similarities with the situation in mice, where
Merkel cells labelled during pregnancy remained EdU+ve in
offspring nine months after birth [44].4. Discussion
The report that T. cruzi can undergo a form of spontaneous
dormancy has highlighted the possibility that the proliferation
status of the parasite could have a role in long-term persistence
and contribute to the high rate of treatment failure [13].
Improvements in tissue processing and imaging procedures
[29] have allowed us to explore this further by providing a
platform to investigate parasite replication in the colon of
chronically infected mice, a tissue that supports long-term
T. cruzi persistence at extremely low levels [27]. Our major
finding is that during chronic infections, the proportion of
intracellular parasites in S-phase is significantly lower than it
is during the acute stage. In acute infections, 70% of parasites
were EdU+ve after using the 1-day protocol, compared with
20% during the chronic stage (figures 3 and 4; electronic sup-
plementary material, figure S3). This is unlikely to reflect
reduced EdU uptake or bioavailability during chronicinfections, as the staining intensity of individual EdU+ve para-
sites was similar during both stages of the disease, with the
only apparent difference being the proportion of amastigotes
that were positive. The most parsimonious explanation is that
T. cruzi amastigotes proliferate at a slower rate in the chronic
stage, at least in this tissue location, and were, therefore, less
likely to be replicating their DNA during the period of EdU
exposure. It is implicit from this that T. cruzi amastigotes
have the capability of responding to environmental signals
that are specific to chronic and/or acute stage disease, such
as nutrient availability or indicators of the immune response.
In the latter case, the observation that immunosuppression
rapidly reactivates the infection [30], suggests that the host
response could be a driver for slow replication, either directly
or indirectly. These observations are in line with previous
reports that amastigote replication and cell cycle kinetics can
be subject to reversible stress-induced inhibition in vitro [26].
A response mechanism of this type could also account for the
correlation between amastigote growth rate and nest size
during acute infections (figure 4).
The heterogeneous nature of labelling during the chronic
stage, with many parasites being EdU−ve (figure 3; electro-
nic supplementary material, figure S3), should not be
interpreted as being indicative of spontaneous dormancy.
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Figure 7. Schematic highlighting the possible fates of host cells and parasites following EdU labelling. The image shows a colon smooth muscle section from a
chronically infected mouse following treatment with the 1-day labelling protocol ( figure 3). EdU labelling (red) appears as yellow against the green background of
parasite fluorescence. (a) Following EdU exposure, the infected cell and parasites could be cleared by the host immune response. (b) There could be outgrowth of
EdU−ve parasites in an infected cell. The EdU+ve subset, which would have been in S-phase during exposure, might enter cell cycle arrest after incorporation. (c) If
EdU incorporation is below the toxicity threshold for cell cycle arrest, amastigote proliferation will lead to serial dilution of the label. (d ) After EdU incorporation by a





within individual host cells is asynchronous [31]. The obser-
vation that some intracellular parasites do not incorporate
EdU reflects that amastigotes exist in a range of replicative
states within individual infected cells, an inference supported
by the cumulative nature of EdU labelling. There are several
possible fates for parasites labelled with EdU during chronic
stage infections, as outlined in figure 7. Given our data,
which show a steady reduction in the percentage of EdU+ve
parasites per infected cell over time (figure 6), continued
growth of these amastigotes and dilution of the label below
the level of detection (figure 7c) would appear to be the most
likely outcome.
Although incorporation of EdU into replicating DNA is
widely used in proliferation studies, it can lead to a DNA
damage response and cell cycle arrest [36–38]. With T. cruzi,
the measurable effect of EdU toxicity is time-dependent [40],
and here, we showed that 6 h exposure in vitro at 1–2 µM
is sufficient to inhibit amastigote replication (figure 2d). There-
fore, studies onT. cruziproliferation, dormancyand persistence
could be confounded if EdU exposure is continuous. In the case
of in vivo administration, EdU toxicity should be less proble-
matic, because of the short clearance time of thymidine
analogues [41]. Consistent with this, we found no detectable
impact of EdU exposure on parasite burden or tissue tropism
in chronically infected mice (electronic supplementary
material, figure S5). In these infection experiments, where
incorporation was employed as an endpoint assay, providing
snapshots of DNA replication within the parasite population,
EdU toxicity would not be expected to compromise the
outcome. This contrasts with in vitro experiments where
EdU exposure can be continuous, resulting in inter-strandcross-linking and double-strand breaks, which trigger DNA
damage signalling and cell cycle arrest [37]. This is a
ubiquitous response in all cells with DNA damage sensing
machinery [45,46]. Spontaneous dormancy has been proposed
as a mechanism that could account for parasite persistence
after therapy [13,47]. However, in T. cruzi, the front-line drug
benznidazole can cause mutagenesis, disruption to DNA
repair pathways and chromosome instability [48,49]. Therefore,
an alternative explanation could be that benznidazole-induced
DNA damage responses trigger cell cycle arrest and a transient
dormant-like state, which protects some parasites from further
drug-induced toxicity, ultimately leading to relapse after the
successful completion of DNA repair.
Our findings do not exclude the possibility that some
parasites might have the potential to enter a canonical
dormant state at specific points in the life cycle. However,
they more strongly suggest that rather than being a discrete
biological stage, a dormancy-like phenotype in T. cruzi
might be better described as representing one end of the
normal proliferation spectrum. The cell cycle plasticity
necessary for this has already been reported in amastigotes
[26]. Therefore, the reduced rate of T. cruzi replication
during the chronic stage could be a phenomenon more
analogous to the biochemical quiescence and reduced pro-
liferation exhibited by Leishmania [19,20], than to the more
definitive dormant state displayed by T. gondii and some
Plasmodium species [3]. Resolving this question and
understanding the mechanisms involved has particular
importance for Chagas disease drug development strategies.
As described in this paper (figures 1 and 2), there are
limitations to the cell tracker dye and DNA labelling
royalsocietypublishing.org/jour
10methodologies that have previously been applied to investi-
gate T. cruzi proliferation and quiescence. Therefore, new
approaches are urgently required.
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